[Effect of IFN treatment for extrahepatic manifestations].
Matsumori
Akira
A
Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine.
D000998:Antiviral Agents / Q000008:administration & dosage*; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000209:etiology* / Q000821:virology; D003449:Cryoglobulinemia / Q000188:drug therapy* / Q000209:etiology* / Q000821:virology; D004359:Drug Therapy, Combination; D005260:Female; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy* / Q000209:etiology* / Q000821:virology; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D016899:Interferon-beta / Q000008:administration & dosage*; D008875:Middle Aged; D009220:Myositis / Q000188:drug therapy / Q000209:etiology* / Q000821:virology; D012254:Ribavirin / Q000008:administration & dosage; D013959:Thyroid Diseases / Q000188:drug therapy* / Q000209:etiology* / Q000821:virology; D016896:Treatment Outcome
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin; D016899:Interferon-beta